The composite incidence of MACE, defined as urgent revascularization, myocardial infarction, hospital admission for heart failure, or all‐cause death, was 30.4% in the PDE5 inhibitor group compared to 36.9% in the non‐PDE5 inhibitor group (171 vs 1482 patients, respectively; p = 0.003; Table 3). This evidence concerns the gene PDE5A and myocardial infarction.